ironwoodpharma.com (IRWD) Cash on Hand per Share

Ironwood Pharmaceuticals, Inc. - graphic logo of issuer IRWD

Ironwood Pharmaceuticals (IRWD) maintains a dominant position in the GI segment, with a patent shield creating significant barriers to entry for competitors. The trend in cash per share confirms this status, with the metric reaching 0.52. Liquidity is expanding through partner licenses and a broad pipeline, while margin scaling via co-marketing strengthens the company's financial independence.

ironwoodpharma.com - IRWD Cash per Single Share (period 07/04/2022 - 11/21/2026)

Comprehensive metric breakdowns and analytics for ironwoodpharma.com (IRWD)

- market price and analyst price targets:
Summary company analysis:IRWD, Ironwood Pharma
Manufactured products of Ironwood Pharmaceuticals

This indicator determines the share of net liquidity per security, allowing for an assessment of the business's ability to maintain operational resilience and fund long-term strategies without raising external capital. By analyzing the current level of cash per share, one can confirm the financial capacity of Ironwood Pharmaceuticals (IRWD) to cover high marketing and lobbying expenses, which, combined with patent protection, confirms the company's fundamental strength.